苯丙酸さん诺龙

苯丙酸さん诺龙
臨床りんしょう資料しりょう
商品しょうひん名めい（英えい语：Drug nomenclature）	Durabolin, others
其他名稱めいしょう	• NPP; • Nandrolone phenpropionate; • 19-Nortestosterone phenylpropionate; • Nandrolone hydrocinnamate; • 19-Nortestosterone 17βべーた-phenylpropionate; • NSC-23162
懷ふところ孕分級きゅう	澳: D ; ;
给药途と径みち	Intramuscular injection
藥物やくぶつ類別るいべつ（英えい语：Drug class）	Androgen; Anabolic steroid; Androgen ester; Progestogen
法律ほうりつ規範きはん狀態じょうたい
法律ほうりつ規範きはん	澳：限きり医い生せい处方（S4）; 加か：Schedule IV; 英えい：Class C; 美よし：附ふ表ひょうIII;
藥物やくぶつ動力どうりょく學がく數かず據よりどころ
生物せいぶつ利用りよう度ど	• Oral: 0.3–2.9% (pigs); • Intramuscular: high
药物代だい谢	Blood (hydrolysis), liver (reduction)
代謝たいしゃ產物さんぶつ	• Nandrolone; • 5αあるふぁ-Dihydronandrolone; • 19-Norandrosterone; • 19-Noretiocholanolone; • Conjugates
生物せいぶつ半はん衰おとろえ期き	• Intramuscular: 2.7 days; • Nandrolone: <4.3 hours
作用さよう時間じかん	• Intramuscular: 5–7 days
排泄はいせつ途と徑みち	Urine
识别信しん息いき
	IUPAC命名めいめい法ほう [(8R,9S,10R,13S,14S,17S)-13-methyl-3-oxo-2,6,7,8,9,10,11,12,14,15,16,17-dodecahydro-1H-cyclopenta[a]phenanthren-17-yl] 3-phenylpropanoate; ;
CAS号ごう	434-22-0
PubChem CID	229455;
ChemSpider	199761;
UNII	KF7Z9K2T3W;
CompTox Dashboard（英えい语：CompTox Chemicals Dashboard） (EPA)	DTXSID2023353 ;
ECHA InfoCard	100.000.502
化学かがく信しん息いき
化学かがく式しき	C27H34O3
摩ま尔质量りょう	406.57 g·mol−1
3D模型もけい（JSmol（英えい语：JSmol））	交互こうご式しき图像;
	SMILES C[C@]12CC[C@H]3[C@H]([C@@H]1CC[C@@H]2OC(=O)CCC4=CC=CC=C4)CCC5=CC(=O)CC[C@H]35;
	InChI InChI=1S/C27H34O3/c1-27-16-15-22-21-11-9-20(28)17-19(21)8-10-23(22)24(27)12-13-25(27)30-26(29)14-7-18-5-3-2-4-6-18/h2-6,17,21-25H,7-16H2,1H3/t21-,22+,23+,24-,25-,27-/m0/s1; Key:UBWXUGDQUBIEIZ-QNTYDACNSA-N;

苯丙酸さん诺龙（英語えいご：Nandrolone phenylpropionate或ある Nandrolone hydrocinnamic，缩写NPP，商品しょうひん名めい为Durabolin）是ぜ一いち种雄お激げき素もと同化どうか類るい固かた醇あつし（AAS）药物，主要しゅよう用よう于治疗乳腺にゅうせん癌がん和わ骨質こっしつ疏鬆症しょう女性じょせい^[8]^[9]^[10]^[11]^[3]，通つう过每周しゅう一いち次じ的てき肌はだ肉にく注射ちゅうしゃ进行^[3]。这类药物过去曾广泛应用よう，但ただし现已逐渐停用よう^[3]^[11]。

19-去さ甲かぶと睾酮（Nandrolone，诺龙），NPP的てき最さい终活性かっせい形式けいしき

参考さんこう文献ぶんけん

^ McEvoy JD, McVeigh CE, McCaughey WJ. Residues of nortestosterone esters at injection sites. Part 1. Oral bioavailability. Analyst. 1998, 123 (12): 2475–8. PMID 10435281. doi:10.1039/a804919j.
^ Kenneth L. Becker. Principles and Practice of Endocrinology and Metabolism. Lippincott Williams & Wilkins. 2001: 1185– [2019-02-17]. ISBN 978-0-7817-1750-2. （原始げんし内容ないよう存そん档于2020-05-17）.
^ ^3.0 ^3.1 ^3.2 ^3.3 ^3.4 ^3.5 William Llewellyn. Anabolics. Molecular Nutrition Llc. 2011: 460–467,193–194. ISBN 978-0-9828280-1-4.
^ ^4.0 ^4.1 Victor A. Rogozkin. Metabolism of Anabolic-Androgenic Steroids. CRC Press. 14 June 1991: 108–. ISBN 978-0-8493-6415-0.
^ ^5.0 ^5.1 John A. Thomas. Drugs, Athletes, and Physical Performance. Springer Science & Business Media. 6 December 2012: 27–29. ISBN 978-1-4684-5499-4.
^ ^6.0 ^6.1 Minto CF, Howe C, Wishart S, Conway AJ, Handelsman DJ. Pharmacokinetics and pharmacodynamics of nandrolone esters in oil vehicle: effects of ester, injection site and injection volume. J. Pharmacol. Exp. Ther. 1997, 281 (1): 93–102. PMID 9103484.
^ ^7.0 ^7.1 ^7.2 存そん档副本ふくほん (PDF). [2019-02-17]. （原始げんし内容ないよう (PDF)存そん档于2010-12-18）.
^ J. Elks. The Dictionary of Drugs: Chemical Data: Chemical Data, Structures and Bibliographies. Springer. 14 November 2014: 660–. ISBN 978-1-4757-2085-3.
^ Index Nominum 2000: International Drug Directory. Taylor & Francis. January 2000: 716–717. ISBN 978-3-88763-075-1.
^ I.K. Morton; Judith M. Hall. Concise Dictionary of Pharmacological Agents: Properties and Synonyms. Springer Science & Business Media. 6 December 2012. ISBN 978-94-011-4439-1.
^ ^11.0 ^11.1 存そん档副本ふくほん. [2019-02-17]. （原始げんし内容ないよう存そん档于2019-08-28）.

[pmid10435281-1] McEvoy JD, McVeigh CE, McCaughey WJ. Residues of nortestosterone esters at injection sites. Part 1. Oral bioavailability. Analyst. 1998, 123 (12): 2475–8. PMID 10435281. doi:10.1039/a804919j.

[Becker2001-2] Kenneth L. Becker. Principles and Practice of Endocrinology and Metabolism. Lippincott Williams & Wilkins. 2001: 1185– [2019-02-17]. ISBN 978-0-7817-1750-2. （原始げんし内容ないよう存そん档于2020-05-17）.

[Llewellyn2011-3] 3.0 ^3.1 ^3.2 ^3.3 ^3.4 ^3.5 William Llewellyn. Anabolics. Molecular Nutrition Llc. 2011: 460–467,193–194. ISBN 978-0-9828280-1-4.

[Rogozkin1991-4] 4.0 ^4.1 Victor A. Rogozkin. Metabolism of Anabolic-Androgenic Steroids. CRC Press. 14 June 1991: 108–. ISBN 978-0-8493-6415-0.

[Thomas2012-5] 5.0 ^5.1 John A. Thomas. Drugs, Athletes, and Physical Performance. Springer Science & Business Media. 6 December 2012: 27–29. ISBN 978-1-4684-5499-4.

[pmid9103484-6] 6.0 ^6.1 Minto CF, Howe C, Wishart S, Conway AJ, Handelsman DJ. Pharmacokinetics and pharmacodynamics of nandrolone esters in oil vehicle: effects of ester, injection site and injection volume. J. Pharmacol. Exp. Ther. 1997, 281 (1): 93–102. PMID 9103484.

[Label-NZ-7] 7.0 ^7.1 ^7.2 存そん档副本ふくほん (PDF). [2019-02-17]. （原始げんし内容ないよう (PDF)存そん档于2010-12-18）.

[Elks2014-8] J. Elks. The Dictionary of Drugs: Chemical Data: Chemical Data, Structures and Bibliographies. Springer. 14 November 2014: 660–. ISBN 978-1-4757-2085-3.

[IndexNominum2000-9] Index Nominum 2000: International Drug Directory. Taylor & Francis. January 2000: 716–717. ISBN 978-3-88763-075-1.

[MortonHall2012-10] I.K. Morton; Judith M. Hall. Concise Dictionary of Pharmacological Agents: Properties and Synonyms. Springer Science & Business Media. 6 December 2012. ISBN 978-94-011-4439-1.

[Drugs.com-11] 11.0 ^11.1 存そん档副本ふくほん. [2019-02-17]. （原始げんし内容ないよう存そん档于2019-08-28）.

[1]

[2]

[7]

[5]

[3]

[4]

[6]

[8]

[9]

[10]

[11]